Adamed across the globe
The international expansion of our company is based on two business models
available around the world
on a global scale
Investments in Asia
At the end of 2017, Adamed acquired a majority stake in the local pharmaceutical company Davipharm, and in April 2023 the purchase transaction of the remaining 30 percent of shares was closed - thus Adamed became the sole owner of the Vietnamese company.
This investment is aimed at strengthening Davipharm's market position by introducing EU-GMP standards in the plant and allowing the company to compete with high-quality imported drugs at prices affordable to Vietnamese patients.
Through the purchase transaction 100 percent of shares in Davipharm, Adamed is building a strong platform for further dynamic expansion in the Asia-Pacific area.
In 2019, Adamed purchased a block of shares in the Italian company Ecupharma. We formed a strategic partnership with the company to support Adamed’s expansion in the Italian market of cardiac medications, and ultimately also in otherareas of therapy.
Ecupharma is a rapidly growing pharmaceutical company active in the fields of neuropsychiatry and urology. Its product portfolio addresses the needs of people with chronic ailments. The company consistently builds its market standing with the support of its loyal customers. Similarly to Adamed, the company also focuses on health conditions affecting the elderly, seeking to respond to contemporary demographic challenges.